Maia Biotechnology’s Ateganosine Shows Promise in Third-Line NSCLC

Maia Biotechnology has reported encouraging Phase II results for ateganosine (THIO), its first-in-class telomerase modifier, in advanced non-small cell lung cancer (NSCLC). In the THIO-101 trial (NCT05208944), ateganosine was administered prior to Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) in patients who had progressed after two or more standard-of-care regimens. The sequential treatment achieved a median progression-free survival (PFS) of 5.6 months, more than double the 2.5-month PFS typically seen with chemotherapy, and a median overall survival (OS) of 17.8 months — 5.8 months higher than recent real-world benchmarks.

The regimen produced a disease control rate (DCR) of 77% compared to 25–35% for chemotherapy. Ateganosine was generally well tolerated, though Grade 3+ treatment-related adverse events occurred in 21.5% of patients, including a Grade 4 liver toxicity case at the highest dose. Maia has initiated a Phase II expansion study to assess the long-term survival benefit in third-line NSCLC.

15-09-2025